More

Should pharmaceutical companies change how they sell, or stick with the status quo? Explore this Deloitte Debate from a life sciences perspective.

In order to succeed and strive beyond 2015 Life Sciences organizations need to make the Supply Chain a strategic priority. Learn what to focus on.

Life Sciences manufacturers will need to reevaluate their current relationships with health care payers and build new capabilities that focus more on the needs of their true customers. Learn more.

By 2012 drugs representing over $74 billion in sales will lose patent protection and therefore face the possibility of competition from generic manufacturers. Explore resources for what these issues mean for the industry

Government-run health care and increased taxes top list of concerns, according to the results of a new Deloitte Center for Health Solutions study.

In a scenario that could represent a future state of pharma, Deloitte presents a provocative scenario in which prescription drugs from multiple pharmaceutical companies would be detailed by independent representatives. Learn more.

Deloitte’s insights on pharmaceutical industry applications for Electronic Health Records (EHRs) provides an overview of how Life Sciences companies should approach leveraging EHR data in their Research efforts. Learn more.

This study profiles comparative effectiveness systems in four developed countries and concludes that, if implemented correctly, comparative effectiveness has the potential to improve care and reduce health care costs for Americans. However, a cut-and-paste approach will not work in the U.S.

Explore the survey results, which offer health care industry leaders and policymakers a timely look at how health care consumerism is evolving and a comprehensive perspective about how Americans approach their health, health care and health insurance.

Transitioning into, and growing within, the molecular diagnostics market will require an actionable strategy. Companies may attain the necessary commercial capabilities through a variety of business models, which will be shaped by both external constraints such as market conditions and customer needs and internal constraints such as existing commercial operations and presence in the diagnostics field. Learn more.